Product Information
FOSFOMYCIN 3 GM SACHET is a generic product labeled by Cipla USA Inc., priced at $26.2204 per EA under NDC 69097057967. Its NADAC has been published 217 times since Aug 10, 2022.
FDA first approved this application on Jan 26, 2022. Its Orange Book therapeutic-equivalence code is AA.
Strength
3 g/1
Manufacturer
Cipla USA Inc.NDC
69097057967
Classification
Generic
Dosage Form
GRANULE, FOR SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FOSFOMYCIN TROMETHAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA211881FDA Approved
1/26/2022
TE Code
AA
On Market Since
1/26/2022
Price Statistics
The NADAC for FOSFOMYCIN 3 GM SACHET has been published 217 times since Aug 10, 2022, and over the history we have for it it has declined 57.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $26.2204 per EA |
|---|---|
| All-time high | $61.5000 (Aug 10, 2022) |
| All-time low | $26.2204 (Sep 23, 2026) |
| 52-week high | $37.0316 |
| 52-week low | $26.2204 |
| Median price | $41.9194 |
| Average price | $43.3843 |
| Largest weekly change | -35.0% (Apr 17, 2024) |
| Weeks tracked | 217 |
| Tracking since | Aug 10, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the FOSFOMYCIN TROMETHAMINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FOSFOMYCIN TROMETHAMINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FOSFOMYCIN 3 GM SACHET?
The current National Average Drug Acquisition Cost (NADAC) for FOSFOMYCIN 3 GM SACHET, manufactured by Cipla USA Inc., is $26.2204 per EA (NDC 69097057967), effective Sep 30, 2026.
How has the price of FOSFOMYCIN 3 GM SACHET changed over time?
Over the history we have for it, the NADAC for FOSFOMYCIN 3 GM SACHET has declined 57.4%. It has been tracked across 217 weekly CMS publications since Aug 10, 2022.
What are the highest and lowest recorded NADAC prices for FOSFOMYCIN 3 GM SACHET?
Since Aug 10, 2022, the NADAC for FOSFOMYCIN 3 GM SACHET has ranged from a low of $26.2204 (Sep 23, 2026) to a high of $61.5000 (Aug 10, 2022), with a median of $41.9194 per EA.
Are there cheaper alternatives to FOSFOMYCIN 3 GM SACHET?
No other NADAC-published product currently shares the active ingredient and strength of FOSFOMYCIN 3 GM SACHET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FOSFOMYCIN 3 GM SACHET?
FOSFOMYCIN 3 GM SACHET (NDC 69097057967) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.